NICE
Guideline
Feb 2016
For professionals
NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.
Topics
Monitoring
Biologics and newer medicines
Jargon explained
therapeutic drug monitoring
drug level
anti-drug antibodies
ELISA
anti-TNF
NHS Lothian
Web page
Dec 2020
Patients and professionals
NHS Lothian's IBD page on monitoring medicines. It explains that people on infliximab or adalimumab have their drug level checked some weeks after starting and then at least yearly, with anti-drug antibodies tested if the level is low.
Topics
Monitoring
Biologics and newer medicines
Jargon explained
drug level
anti-drug antibodies
anti-TNF
shared care
Crohn's & Colitis UK
Guide
Jun 2024
For patients
A guide to infliximab, an anti-TNF biologic given by drip or as an injection under the skin. It lists the original brand Remicade and biosimilars such as Remsima, Inflectra, Flixabi and Zessly, and explains checks before starting, that your team may measure drug and antibody levels in your blood, and possible side effects.
Topics
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
infusion
subcutaneous
biosimilar
drug levels
antibodies
Crohn's & Colitis UK
Guide
Sep 2024
For patients
A guide to adalimumab, an anti-TNF biologic you inject under your skin with a pen or syringe. It explains that Humira was the first brand and Amgevita, Hyrimoz, Idacio, Imraldi and Yuflyma are biosimilars, and that blood tests may check drug and antibody levels.
Topics
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
biosimilar
antibodies
subcutaneous injection
Crohn's & Colitis UK
Guide
Jul 2023
For patients
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
biosimilar
anti-TNF
IL-23 inhibitor
JAK inhibitor
advanced therapy
Cochrane
Systematic review
May 2025
Patients and professionals
Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.
Topics
Biologics and newer medicines
Jargon explained
IL-12/23
induction
certainty of evidence
Frontline Gastroenterology (via PMC)
Guide
Nov 2025
For professionals
A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.
Topics
Medicines
Surgery
Monitoring
Jargon explained
top-down
step-up
therapeutic drug monitoring
ileocaecal resection
Rutgeerts score
immunogenicity
ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Aug 2026
For professionals
The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.
Topics
Children and young people
Diet and nutrition
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
therapeutic drug monitoring
exclusive enteral nutrition
endoscopic remission
New England Journal of Medicine
Study
Apr 2010
Patients and professionals
A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.
Topics
Biologics and newer medicines
Immunosuppressants
Research
Jargon explained
combination therapy
steroid-free remission
mucosal healing
randomised controlled trial
ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Feb 2021
For professionals
European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.
Topics
Children and young people
Medicines
Diet and nutrition
Biologics and newer medicines
Jargon explained
paediatric
penetrating disease
stricturing disease
exclusive enteral nutrition
anti-TNF
immunomodulator
therapeutic drug monitoring
Cochrane
Systematic review
May 2020
Patients and professionals
Cochrane concluded that adalimumab works for keeping Crohn's in remission, including in people who had already tried another anti-TNF drug. Whether it helps after bowel surgery is still unclear.
Topics
Biologics and newer medicines
Jargon explained
anti-TNF
maintenance
quiescent
New England Journal of Medicine
Study
Jul 2024
Patients and professionals
A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.
Topics
Biologics and newer medicines
Research
Jargon explained
non-inferiority
endoscopic remission
anti-TNF